Publications

Export 113 results:
[ Auteur(Desc)] Title Type Année
Filtres: First Letter Of Last Name is G  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
G
Gajewski PA, Turecki G, Robison AJ.  2016.  Differential Expression of FosB Proteins and Potential Target Genes in Select Brain Regions of Addiction and Depression Patients.. PLoS One. 11(8):e0160355.
Galfalvy H, Haghighi F, Hodgkinson C, Goldman D, Oquendo MA, Burke A, Huang Y-Y, Giegling I, Rujescu D, Bureau A et al..  2015.  A genome-wide association study of suicidal behavior.. Am J Med Genet B Neuropsychiatr Genet. 168(7):557-63.
Gallino D, Devenyi GA, Germann J, Guma E, Anastassiadis C, M Chakravarty M.  2019.  Longitudinal assessment of the neuroanatomical consequences of deep brain stimulation: Application of fornical DBS in an Alzheimer's mouse model.. Brain Res. 1715:213-223.
Gammer I, Bedford R, Elsabbagh M, Garwood H, Pasco G, Tucker L, Volein A, Johnson MH, Charman T.  2015.  Behavioural markers for autism in infancy: scores on the Autism Observational Scale for Infants in a prospective study of at-risk siblings.. Infant Behav Dev. 38:107-15.
Gan-Or, iv Z, Montplaisir JY, Ross JP, Poirier J, Warby SC, Arnulf I, Strong S, Dauvilliers Y, Leblond CS, Hu MTM et al..  2017.  The dementia-associated APOE ε4 allele is not associated with rapid eye movement sleep behavior disorder.. Neurobiol Aging. 49:218.e13-218.e15.
Gangarossa G, Guzman M, Prado VF, Prado MAM, Daumas S, Mestikawy SEl, Valjent E.  2016.  Role of the atypical vesicular glutamate transporter VGLUT3 in l-DOPA-induced dyskinesia.. Neurobiol Dis. 87:69-79.
Gao T, Hu Y, Qin Z, Cao R, Liu S, Mei S, Meng X.  2019.  The role of school connectedness and maladaptive cognitions in the association between stress and Internet addiction: A serial mediation model.. Perspect Psychiatr Care.
Gao T, Meng X, Qin Z, Zhang H, Gao J, Kong Y, Hu Y, Mei S.  2018.  Association between parental marital conflict and Internet addiction: A moderated mediation analysis.. J Affect Disord. 240:27-32.
Gardon O, Faget L, P Chung CSin, Matifas A, Massotte D, Kieffer BL.  2014.  Expression of mu opioid receptor in dorsal diencephalic conduction system: new insights for the medial habenula.. Neuroscience. 277:595-609.
Gariépy G, Kaufman JS, Blair A, Kestens Y, Schmitz N.  2015.  Place and health in diabetes: the neighbourhood environment and risk of depression in adults with type 2 diabetes.. Diabet Med. 32(7):944-50.
Gariépy G, McIlwaine SV, Schmitz N, Shah JL.  2018.  An approach to sample size calculation for research on duration of untreated psychosis.. Schizophr Res.
Gariépy G, Iyer SN.  2018.  The Mental Health of Young Canadians Who Are Not Working or in School.. Can J Psychiatry. :706743718815899.
Gariépy G, Blair A, Kestens Y, Schmitz N.  2014.  Neighbourhood characteristics and 10-year risk of depression in Canadian adults with and without a chronic illness.. Health Place. 30:279-86.
Gariépy G, Thombs BD, Kestens Y, Kaufman JS, Blair A, Schmitz N.  2015.  The Neighbourhood Built Environment and Trajectories of Depression Symptom Episodes in Adults: A Latent Class Growth Analysis.. PLoS One. 10(7):e0133603.
Gaumer B, MJ Fleury.  2008.  CLSCs in Quebec: thirty years of community action.. Soc Work Public Health. 23(4):89-106.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Schlaefke S.  2014.  Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
Gauthier S, Herrmann N, Rosa-Neto P.  2018.  Optimal use of cholinergic drugs in Alzheimer's disease.. Brain.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, Middleton LT.  2016.  Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 12(1):60-4.
Gauthier S, Ng KPin, Pascoal TA, Mathotaarachchi S, Chung C-O, Benedetti AL, Shin M, Kang MSu, Li X, Ba M et al..  2017.  Author response: Neuropsychiatric symptoms predict hypometabolism in preclinical Alzheimer disease.. Neurology. 89(18):1931.
Gauthier S.  2017.  Research update on Alzheimer's disease and introduction to the Expert Review of Neurotherapeutics special issue.. Expert Rev Neurother. 17(1):1-2.
Gauthier S, Proaño JVoltaire, Jia J, Froelich L, Vester JChristophe, Doppler E.  2015.  Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials.. Dement Geriatr Cogn Disord. 39(5-6):332-47.
Gauthier S, Robillard J, de Champlain J.  2017.  Progress in transnational scientific and ethics review: Commentary on the proposal for a single North American review board for research on dementia.. Alzheimers Dement.
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.  2015.  Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.. J Alzheimers Dis. 48(2):473-81.

Pages